Literature DB >> 21301815

Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics.

Fu De Yang1, Xiang Qun Wang, Xiu Ping Liu, Ke Xin Zhao, Wei Hong Fu, Xue Ru Hao, Xing Li Zhang, Guo Shu Huang, Sheng Cai Qu, Jing Shen Bai, Xu Feng Huang, Thomas R Kosten, Xiang Yang Zhang.   

Abstract

OBJECTIVE: The rate-corrected electrocardiographic QT (QTc) interval may significantly increase in patients with schizophrenia taking antipsychotics. The objective of this naturalistic study was to assess the prevalence of prolonged QTc interval in a large population of inpatients with chronic schizophrenia and to explore QTc relationship with demographic variables and prescribed treatments.
MATERIALS AND METHODS: Electrocardiograms were obtained from age- and sex-matched 456 controls and 1,006 inpatients with schizophrenia (male/female = 689/317) taking antipsychotics. QTc prolongation was defined as a mean value of two standard deviations above the controls. The adjusted relative risk was calculated using logistic regression analysis.
RESULTS: QTc prolongation was present in 45 (4.5%) of 1,006 patients overall. Fewer men (3.2%, 22 of 689) than women (7.3%, 23 of 317) displayed QTc prolongation (p < 0.004). Moreover, QTc intervals were shorter in male (391 ± 31 ms) than female subjects (400 ± 37 ms) (p < 0.001). Clozapine was found to produce a longer QTc intervals compared to risperidone and typical antipsychotics. Furthermore, multiple regression analysis showed that significant predictors for QTc prolongation were comorbid cardiovascular disease, antipsychotic types, sex, and age (all p < 0.01).
CONCLUSION: Our present findings suggest that there are sex differences in the prevalence of QTc prolongation and QTc lengthening in schizophrenia. Antipsychotic types are risk factors for QTc prolongation, and risks are substantially higher for clozapine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21301815     DOI: 10.1007/s00213-011-2188-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  Prolonged QTc intervals in medicated patients with schizophrenia.

Authors:  Siow Ann Chong; Alvin Lum; Hern Yee Goh; Yiong Huak Chan
Journal:  Hum Psychopharmacol       Date:  2003-12       Impact factor: 1.672

Review 2.  Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.

Authors:  J Czekalla; S Kollack-Walker; C M Beasley
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

3.  QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.

Authors:  J G Reilly; S A Ayis; I N Ferrier; S J Jones; S H Thomas
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 4.  Antipsychotic drugs and QT prolongation.

Authors:  Claudia Stöllberger; Johannes O Huber; Josef Finsterer
Journal:  Int Clin Psychopharmacol       Date:  2005-09       Impact factor: 1.659

Review 5.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Authors:  A H Glassman; J T Bigger
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

6.  QTc variability in schizophrenia patients treated with antipsychotics and healthy controls.

Authors:  Maria A Rettenbacher; Ursula Eder-Ischia; Angelika Bader; Monika Edlinger; Alex Hofer; Martina Hummer; Georg Kemmler; Elisabeth M Weiss; Monika Hochleitner; W Wolfgang Fleischhacker
Journal:  J Clin Psychopharmacol       Date:  2005-06       Impact factor: 3.153

Review 7.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Sex differences in the evolution of the electrocardiographic QT interval with age.

Authors:  P M Rautaharju; S H Zhou; S Wong; H P Calhoun; G S Berenson; R Prineas; A Davignon
Journal:  Can J Cardiol       Date:  1992-09       Impact factor: 5.223

Review 9.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

10.  New Generation Antipsychotic Drugs and QTc Interval Prolongation.

Authors:  W VictorR Vieweg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-10
View more
  15 in total

Review 1.  Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Hiroyuki Uchida
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

Review 2.  Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.

Authors:  Gregory Kruse; Bruce J O Wong; Mei Sheng Duh; Patrick Lefebvre; Marie-Hélène Lafeuille; John M Fastenau
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

3.  Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.

Authors:  Xiang Yang Zhang; Da Chun Chen; Yun Long Tan; Mei Hong Xiu; Jingyi Cui; Li Hui; Fu De Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2013-08-21       Impact factor: 4.530

Review 4.  QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.

Authors:  Mehrul Hasnain; W Victor R Vieweg
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

5.  Lack of tolerable treatment options for patients with schizophrenia.

Authors:  Leslie Citrome; Anna Eramo; Clement Francois; Ruth Duffy; Susan N Legacy; Steve J Offord; Holly B Krasa; Stephen S Johnston; Alice Guiraud-Diawara; Siddhesh A Kamat; Patricia Rohman
Journal:  Neuropsychiatr Dis Treat       Date:  2015-12-16       Impact factor: 2.570

Review 6.  A literature-based algorithm for the assessment, management, and monitoring of drug-induced QTc prolongation in the psychiatric population.

Authors:  M Zolezzi; L Cheung
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-24       Impact factor: 2.570

7.  Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders.

Authors:  Wilbert S Aronow; Tatyana A Shamliyan
Journal:  Ann Transl Med       Date:  2018-04

8.  Selective acquired long QT syndrome (saLQTS) upon risperidone treatment.

Authors:  Maciej Jakub Lazarczyk; Zahir A Bhuiyan; Nicolas Perrin; Panteleimon Giannakopoulos
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

Review 9.  Etiology of cardiovascular disease in patients with schizophrenia: current perspectives.

Authors:  Murat Emul; Tevfik Kalelioglu
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-01       Impact factor: 2.570

Review 10.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.